These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 15815733

  • 1. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S, Spigset O, Slørdal L.
    Tidsskr Nor Laegeforen; 2005 Apr 07; 125(7):875-8. PubMed ID: 15815733
    [Abstract] [Full Text] [Related]

  • 2. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov 07; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 07; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 4. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E.
    Tidsskr Nor Laegeforen; 2002 Feb 20; 122(5):476-80. PubMed ID: 11961974
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 20; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM, Weber RJ, McKaveney TP, Ansani NT, Towers AL.
    Ann Pharmacother; 2003 Sep 20; 37(9):1203-13. PubMed ID: 12921500
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
    Davies NM, Jamali F.
    J Pharm Pharm Sci; 2004 Oct 29; 7(3):332-6. PubMed ID: 15576013
    [Abstract] [Full Text] [Related]

  • 18. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW.
    Ned Tijdschr Geneeskd; 2004 Oct 30; 148(44):2162-4. PubMed ID: 15559407
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.